• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » UK court shoots down Abbott bid for injunction in TMVR patent spat with Edwards

UK court shoots down Abbott bid for injunction in TMVR patent spat with Edwards

May 8, 2019 By Fink Densford

Edwards Lifesciences, Abbott

Edwards Lifesciences (NYSE:EW) recently claimed a win in a UK-based patent spat with Abbott (NYSE:ABT) over IP related to each company’s respective transcatheter mitral valve repair devices after a UK court shot down a bid from Abbott for a preliminary injunction.

In the suit, filed on January 28, Abbott claimed that Edwards is infringing on two of its patents with its Pascal TMVR system and sought an interim injunction to keep Edwards from marketing the device in the UK, claiming that the company’s entry into the market could cause irreparable harm.

Edwards denied the infringement and counterclaimed for invalidity on a basis of lack of novelty and obviousness, according to court documents.

After applying for an interim injunction, Abbott applied for an expedited trial, which was granted in March with a slated date of December 2019. A judgement is expected to be delivered by January of next year, according to the documents.

Currently, TMVR procedures are not covered by the UK’s National Health Service, resulting in a very small number of such procedures in the country, according to court documents. “A very small number of [Abbott’s] MitraClip implantations are carried out each year in the United Kingdom at a total of 18 hospitals,” with “several months” between procedures, court documents read.

Edwards said that in light of the suit, it limited its activities in the region to a total of 10 procedures with its Pascal device, according to court documents. Abbott claims that those 10 procedures could still affect the company and its MitraClip brand in a number of ways, including directly decreasing sales.

Abbott also asserted a number of other claims, including the need for retraining surgeons who used the Pascal device, the disassociation of the TMVR procedure with the ‘Mitraclip’ brand, damage to its relationship with consumers, physicians and others.

Chicago-area based Abbott also “characterized the Pascal device as a copycat product, which was piggybacking on investment and training that had been carried out by Abbott,” Mr Justice Henry Carr wrote in court documents.

“As I observed at the hearing, this type of advocacy relied on too many animal analogies. The allegation that Pascal was a copycat product should never have been made,” Carr wrote. “First, it appears on the evidence before me to be entirely unjustified. Secondly, even if justified, it is irrelevant to the claim of patent infringement advanced by Abbott. If Abbott wish to allege copying, then they should bring a claim for infringement of unregistered design right, if any such right subsists. The courts of the United Kingdom have repeatedly said that allegations of copying are irrelevant to patent infringement. Whilst it is no doubt tempting, nonetheless, to assert copying, it is a sign of weakness rather than strength when this is done.”

Mr Justice Henry Carr did not agree with the majority of Abbott’s other arguments, adding that “in the light of Edwards’ undertaking to limit its activities until judgement, subject to a liberty to apply, to 10 implantations in two hospitals, I do not consider that Abbott will sufficient irreparable prejudice between now and judgement.”

Carr went on to conclude that “even if Abbott will suffer some irreparable prejudice as a result of Edwards’ limited launch, then such prejudice is clearly outweighed by the irreparable harm that would be suffered by Edwards if the injunction is granted,” and refused injunctive relief for both parties.

Edwards lauded the decision in an email to MassDevice.com, saying that it plans to continue its launch in the UK.

“We are pleased to share that the UK Court denied Abbott’s motion for a preliminary injunction, and also ordered Abbott to cover the majority of Edwards’ legal costs in this matter. This means that we can continue with our previously established disciplined commercial launch plans in the UK. We are proud that Pascal represents significant research and development in response to the needs of the clinical community.  Given the burden and complexity of mitral valve disease, we believe this is the best possible outcome for patients. We have always maintained that a broad range of proven therapies will be necessary to address the unmet needs of these patients and to help raise awareness of significant undertreatment,” a spokesperson for Edwards Lifesciences said.

Last month, Edwards saw share prices fall slightly despite posting Street-beating first quarter earnings results that saw the growth on the bottom line of over 20%.

Filed Under: Cardiovascular, Featured, Legal News, Replacement Heart Valves Tagged With: Abbott, Edwards Lifesciences

In case you missed it

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Acutus Medical ticks up on revenue beat, missed EPS in Q2 results
  • ResMed expects steady growth over the next year
  • Ambu is letting go of 200 employees
  • Medtronic has Class I recall for low-shock risk in ICDs
  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance

RSS From Medical Design & Outsourcing

  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]

Primary Sidebar

DeviceTalks Weekly

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy